

9-2017

Reduction of Cognitive Decline in Patients with or at High Risk for Diabetes

Gladys E. Maestre

The University of Texas Rio Grande Valley, gladys.maestre@utrgv.edu

Follow this and additional works at: https://scholarworks.utrgv.edu/som_pub



Part of the [Diseases Commons](#)

Recommended Citation

Maestre, Gladys E., "Reduction of Cognitive Decline in Patients with or at High Risk for Diabetes" (2017).
School of Medicine Publications and Presentations. 28.
https://scholarworks.utrgv.edu/som_pub/28

This Article is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has been accepted for inclusion in School of Medicine Publications and Presentations by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact justin.white@utrgv.edu, william.flores01@utrgv.edu.



Published in final edited form as:

Curr Geriatr Rep. 2017 September ; 6(3): 188–195. doi:10.1007/s13670-017-0216-y.

Reduction of Cognitive Decline in Patients with or at High Risk for Diabetes

Gladys E. Maestre, MD, PhD¹

¹Dept. Biomedical Sciences, Div. Neurosciences, University of Texas Rio Grande Valley School of Medicine, Brownsville TX 78520

Abstract

Purpose of review—The incidence of Alzheimer’s disease and related disorders is expected to triple by 2050. People with type 2 diabetes and prediabetes have a higher risk of cognitive dysfunction, including Alzheimer’s disease and vascular dementia. Controversy remains about when and how to prevent and treat cognitive dysfunction in people with or at high risk of diabetes.

Recent findings—In our review of ongoing clinical trials, we have found that there has been an increase in the number of studies assessing the efficacy of pharmacological and non-pharmacological approaches to prevent or slow down cognitive impairment among people with or at high risk of diabetes.

Summary—Despite the considerable risk of cognitive impairment in people with diabetes and prediabetes, there is not enough evidence to support a specific treatment to prevent or slow mild cognitive impairment, or progression to Alzheimer’s disease or related disorders. Several ongoing trials are attempting to identify the usefulness of several compounds, as well as lifestyle changes including exercise and diet. Direct mechanisms linking diabetes to cognitive decline have not been elucidated.

Keywords

Alzheimer’s Disease; Dementia; Mild Cognitive Impairment; Clinical Trials; Insulin; Prediabetes

Introduction

The number of people worldwide living with dementia will double almost every 20 years, reaching 74.7 million in 2030 and 131.5 million in 2050 [1]. It is estimated that worldwide, approximately 2% (825,000) cases of Alzheimer’s disease (AD) – the main cause of age-related dementia – are currently attributable to diabetes, including 3% (nearly 175,000) in the US [2]. Of considerable concern is the large and rapidly growing number of older adults

Correspondence to: Gladys E. Maestre, MD, PhD, Dept. Biomedical Sciences, Div. Neurosciences, School of Medicine, University of Texas Rio Grande Valley, One West University Blvd, BROBL 106, Brownsville, TX 78520, gladys.maestre@utrgv.edu.

Compliance with Ethical Guidelines

Conflict of Interest

Gladys Maestre reports grants from the National Institute of Aging- Fogarty International Center, during the conduct of the study.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

who have prediabetes, a metabolic condition associated with obesity that significantly increases the risk of developing type 2 diabetes [3]. In the U.S., for example, nearly 50% of adults have diabetes or pre-diabetes [4], suggesting that there is a substantial population that may have a dual risk of developing both diabetes and cognitive decline [5].

Evidence associating type 2 diabetes and severe cognitive decline emerged from epidemiological studies [6, 7]. The clinical and molecular determinants whereby diabetes increases the risk of cognitive impairment and AD remain to be elucidated. However, dysregulation of insulin might be directly linked to the increased vulnerability of people with or at high risk of type 2 diabetes. The role of insulin in the brain continues to be mysterious. Before the work of Chowers, Lavy and Halpern [8] demonstrated that insulin promoted the uptake of glucose by the brain, it was believed that the brain was insensitive to insulin. However, insulin receptors in the brain [9] were in fact found to be enriched in the olfactory areas and associated limbic regions [10], areas of pivotal importance for cognition and mood. Since then, the notion that insensitivity to insulin in the brain would lead to 'diabetes of the brain' [11], which would manifest as cognitive dysfunction, has emerged. Epidemiological studies have shown that Alzheimer's disease is exceedingly common among people suffering type 2 diabetes [16]. It has been reported that intranasal administration of insulin in small groups of adults with mild cognitive impairment (MCI) or AD has been associated with improvement of memory [12, 13], structural brain changes, and cerebral spinal fluid (CSF) [14] markers of AD pathology. Interestingly, this effect is more evident with short-term insulin and among individuals who do not carry allele 4 of the apolipoprotein E (APOE). In addition, administration of metformin – a medication that improves glucose control and helps reduce hyperinsulinemia – to a small group of elderly individuals who are overweight or obese (without treated diabetes) or who have MCI, over a period of 12 months, was associated with improvements in memory [15]. However, the prevention, prognosis, and management of cognitive decline associated with diabetes and prediabetes remain uncertain.

Cognitive Decline in Patients with or at High Risk of Diabetes

Cognitive performance in neuropsychological tests of Individuals with type 2 diabetes is lower than people of their same age, sex and education, across all ages and beginning in the very early stages of dysglycemia [17, 18]. Not all cognitive domains are affected equally: verbal memory, information processing speed, attention, and executive functioning are particularly affected [19]. The magnitude of these changes varies from subtle to mild cognitive impairment and dementia [20]. Determinants of the type of impairment, speed of decline, and progression to either Alzheimer's disease or vascular dementia, are not known. In individuals with controlled type 2 diabetes, insulin-related variables (i.e. fasting insulin, C-peptide, and the Homeostasis Model Assessment of Insulin Resistance (HOMA2-IR)) are unrelated to the variance in cognitive performance, suggesting that peripheral insulin and cerebral insulin resistance might play different roles in cognition, at least among people with type 2 diabetes [21].

Insulin dysregulation may affect the brain beyond alterations in glucose metabolism. Insulin is a potent neuromodulator [22], able to potentiate the NMDA, AMPA, and GABA receptors

that are important mediators of synaptic plasticity [23]. Also, Insulin-receptors are preponderantly present in areas of the brain implicated in cognition [24], participating in several important processes underlying cognitive functioning, such as neuronal survival and firing [25]. However, the mechanisms that may be activated when there are peripheral – out of the brain – abnormalities of insulin levels remain unclear. Most of the available insulin in the brain is derived from circulating blood levels, and there is little *de novo* synthesis in the brain [26]. Insulin crosses the brain-blood barrier using active transporters that are saturable [27, 28], and the binding of insulin to the receptors can also be modulated by a wide array of factors, for example, as bacterial infections increase their uptake [29], while steroids decrease it [30]. In parallel with AD, reduced insulin sensitivity, as well as decreased density of insulin receptors in the brain, has been reported to be associated with increased accumulation of A β and tau protein hyperphosphorylation [31, 32].

In AD patients, the concentrations of insulin in the CSF are decreased, while they are raised in the blood plasma, and this is more evident in the advanced stages of AD and patients without APOE-4 allele [33]. Concurrently, there are other abnormalities that may or may not be related to cerebral insulin alterations. Several experimental pieces of evidence support the link between AD and type 2 diabetes through mitochondrial alterations and oxidative stress, altered energy and glucose metabolism, cholesterol modifications, and dysfunctional protein O-GlcNAcylation [22].

Alzheimer's Disease Biomarkers in or at High Risk of Diabetes

Imaging and biomarker studies in humans are just beginning to provide insight into how diabetes and prediabetes may influence the progression of Alzheimer's disease. Insulin resistance does not appear to influence CSF AD-related biomarkers (amyloid β -peptide (A β), total tau and tau phosphorylated at the Thr181 epitope) in cognitively healthy individuals [34]. However, in the same study, a significant relationship was reported between continuous values of plasma insulin and CSF A β /tau, driven by the correlation between insulin levels and levels of tau protein, and thus suggesting a link between insulin resistance and neuronal degeneration. This finding is not surprising, as studies in animal models have demonstrated an association between hyperinsulinemia and tau pathology [35]. Imaging studies assessing the accumulation of AD biomarkers in the brain tissue in humans are scarce. TAUPET is an ongoing study (NCT03024944) assessing whether diabetes status type 2 diabetes and pre-diabetes, compared with normal glucose tolerance, is associated with increased tau accumulation in the brain of a community-based group of middle-aged Caribbean-Hispanics. Similar strategies will provide clarification as to the effect of insulin resistance in the progression of the neurodegenerative and vascular changes associated with AD.

Emerging Therapeutic Approaches

Advances in the knowledge of AD and type 2 diabetes have encouraged the development of treatments for preventing the pathogenic events that lead to severe cognitive impairment in individuals with prediabetes, metabolic syndrome or diabetes (Table 1), focused mainly on reducing brain insulin resistance. Clinical trials were identified using the public website

www.clinicaltrials.gov, which has tracked clinical trials since 2007. On May 1, 2017, there were twelve registered studies with the goal of either preventing the progression of MCI to AD, preventing MCI in people with or at high risk of type 2 diabetes and nine of them were ongoing. The studies are being carried out in four countries, and only two of them have concluded at the time of writing this review.

Glucagon-Like Peptide 1 (GLP1)

Glucagon-like peptide 1 (GLP1) agonists have been shown to offer neuroprotection [36], reverse brain insulin resistance [37, 38], reduce amyloid- β peptide accumulation and cytotoxicity [39], and decrease tau hyper-phosphorylation [40] in cellular and animal models of AD. Exenatide is one of the GLP-1 agonists that has been shown to decrease insulin resistance in the brain [37] and has already demonstrated clinical effectiveness to improve cognitive performance in patients with Parkinson's disease [41]. The purpose of the clinical trial using Exenatide NCT01255163 was to prevent/slow the progression of cognitive dysfunction and related biomarkers in dysglycemic/prediabetic patients with MCI. The intervention consisted of subcutaneous injections of 2 mg long-acting exenatide once weekly.

Acetylcholinesterase inhibitors (AChEI)

The most widely used drugs for the symptomatic treatment of AD in clinical practice are AChEI. Besides its cholinergic effect, Galantamine has significant antiinflammatory effects [42], suppressing serum TNF and IL-6 levels, and decreasing body weight and abdominal adiposity and alleviating insulin resistance and fatty liver in mice with high-fat diet-induced obesity [43]. In AD, there is a significant state of neuroinflammation that contributes to the neurodegenerative process, especially the activated microglia [44]. The clinical trial NCT02283242 was established with the purpose of investigating the effects of Galantamine on inflammatory markers, as well as on abdominal visceral and epicardial fat and oxidative stress in patients with metabolic syndrome. The intervention consisted of the oral use of Galantamine for 12 weeks (8 mg for four weeks and 16 mg for eight weeks).

Vitamin D3 - Cholecalciferol

Meta-analyses of cross-sectional studies have reported impaired cognitive function among individuals with insufficient levels of Vitamin D [45], while analyses of longitudinal studies revealed a nearly two-fold risk of incident cognitive impairment [46] and a 20% increased risk of developing AD [47]. However, clinical interventional studies have failed to show that supplementation with Vitamin D improves cognitive outcomes in individuals [48]. The purposes of the clinical trial NCT02416193 were to determine (1) the effect of vitamin D3 supplementation on cognitive function and (2) the effect of vitamin D3 supplementation on diabetes self-management in participants with type 2 diabetes who have symptoms of cognitive impairment but are not demented.

Resveratrol

Resveratrol is a potent caloric restriction-mimetic, able to penetrate the brain-blood barrier and showing positive influence on human cerebral blood flow [49], glucose control [50] and

verbal episodic memory performance [51]. It is found in grapes, red wine, peanuts and certain berries. The vast majority of studies dealing with the biological activity of resveratrol have been carried out *in vitro* and, to a lesser extent, in animal models [52]. Relatively few human clinical trials have been performed so far, and the main obstacle to translating the output of *in vitro* studies using resveratrol on humans relies on rapid metabolization, and consequentially, low bioavailability of the molecule [53].

Not only is there no clear dose-response concerning consumption of resveratrol and its metabolites, but in the brain, the availability or lack thereof of any of these metabolites is even lower than in blood [53]. Furthermore, the dose required to maximize effects without safety concerns is not yet known, and it is uncertain whether chronic ingestion of low resveratrol doses can exert more benefits than short-time exposures to high resveratrol doses [52].

In animal models, resveratrol influences the levels of several inflammatory response markers found to be elevated in diabetes, and other chronic disorders [54–56]. In humans, conflicting results [57, 58] and the lack of confirmation of several mechanisms involved in its activity in ‘preclinical’ models [52] preclude its current pharmacological use in patients with or at high risk of diabetes, or at high risk for development of cognitive impairment. However, recent clinical trials support the notion that resveratrol is capable of increasing cerebral blood flow during task performance [59, 49, 60] and enhancing oxygen extraction [49], reducing glycosylated hemoglobin A1c, preserving hippocampus volume, and improving hippocampus resting state functional connectivity in at-risk patients for dementia [61]. A randomized, double-blind clinical trial phase 1 (NCT02502253) will evaluate the effects of a Bioactive Dietary Polyphenol Preparation (BDPP), a combination of two nutraceutical preparations (grape seed polyphenolic extract, and resveratrol) in mood and cognition of patients with MCI and prediabetes or type 2 diabetes.

Improved Control of Vascular Risk Factors

A growing body of evidence indicates that potentially modifiable cardiovascular risk factors may play an important role in the high prevalence of AD, as well as in type 2 diabetes [62]. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) [63] – a 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people – found that there were significant intervention effects on the primary outcome (overall cognition), main cognitive secondary outcomes (executive functioning and processing speed), and other secondary outcomes (body mass index, dietary habits, and physical activity). However, it has not been clearly determined whether these vascular factors also affect AD progression itself and thus whether controlling vascular conditions can slow this progression [64]. Some studies show that there is a lower conversion rate from MCI to dementia, and lower progression of AD in patients in whom all vascular risk factors were treated compared to those in whom only some of the risk factors were treated [65, 66]. However other studies show no clinical impact [67] or improvement of cognition in overweight or obese patients with type 2 diabetes [68].

The COVARAD is an ongoing clinical trial (NCT01423396) that compares the effect of “optimal” vs. “standard” care of hypertension, diabetes and dyslipidemia in AD patients, with the underlying hypothesis that those with stricter control of the risk factors will exhibit a slower cognitive decline. The BFIT is another clinical trial (NCT03117829) that compares cerebral blood flow, cognitive measures, and metabolomics markers in 40 sedentary (exercise <1 hour/week) participants who are 45–65 years of age, have impaired fasting glucose and are cognitively normal, and that undergo a 12-week diet and exercise intervention.

Dietary Pattern

Changes to diet have been recognized as a promising target for prevention of cognitive decline and AD [69, 70]. However, the optimal diet necessary to prevent the development of Alzheimer’s disease and the progression of cognitive decline has yet to be identified, particularly when the exposure to nutritional patterns has occurred for several decades and the individual may already be suffering from obesity, dyslipidemia, and/or diabetes. It is less problematic to study naturally occurring dietary patterns that are associated with fewer of these consequences, including dementia. Indeed, this approach has allowed the identification of the Mediterranean dietary pattern has been linked most consistently to lower Alzheimer’s disease incidence [71], and a Japanese pattern consisting of a high intake of fish, fruits and vegetables, potatoes, mushrooms, seaweeds, pickles, and soybeans that were also related to a lower risk of dementia [72]. At the same time, adverse dietary patterns have been identified. For example, a pro-inflammatory dietary pattern characterized by higher intake of red meat, processed meat, peas and legumes, and fried food, and lower intake of whole grains was found to be associated with higher inflammatory markers and accelerated cognitive decline at older ages [73]. The ongoing BEAM study (NCT02984540) compares the effects of a low-carbohydrate diet and a low fat diet for adults with mild memory loss and adults with pre-diabetes. The data collected will help determine changes in cognitive function, brain structure and function, and levels of certain proteins and hormones in body fluids.

Diets containing a preponderance of low-glycemic index food, i.e. containing carbohydrates leading to a slower release of glucose (e.g., rye bread) [74], low in saturated fats [75] and low in sodium [76], have been found to be associated with less cognitive impairment in old age. However, there is little consensus about recommendations, because of conflicting results and lack of randomized control trials. The MEAL-2 study (NCT02463084) was designed to compare the effects of a one-month diet high in saturated fat, glycemic index, and salt, to a diet low in these nutritional parameters on memory and other cognitive functions, magnetic resonance imaging measures of brain structure, function, and perfusion, as well as on blood and cerebrospinal fluid levels of amyloid-beta ($A\beta$), insulin, lipids cytokines, apolipoprotein E, apolipoprotein J, cortisol, soluble low density lipoprotein receptor-related protein, and glucose, in middle-aged adults (45–65 years of age) with normal cognition or mild cognitive impairment and prediabetes.

Meal frequency and timing, and calorie content of the diet have been suggested as potential modulators and influencers of disease trajectory during lifecourse [77, 78]. Diets that include calorie restriction and fasting have been associated with improved cognitive

performance, but few randomized clinical trials have been performed. A randomized controlled trial (NCT02460783) was established to test the effect of calorie restriction – defined as 500–600 calories a day for two consecutive days, followed by non-restricted eating for 5 days (5–2 CR) – on memory and executive function, resting state default mode network activity, brain metabolism, and AD biomarkers, in overweight to obese women and men (between 55 and 70 years of age).

Conclusions

Evidence suggests that patients with type 2 diabetes are at an increased risk of developing AD and that insulin resistance can lead to cognitive impairment [16, 79] Because both conditions are increasing exponentially, and only palliative treatments exist; new therapeutic targets for prevention, treatment and reversal of the decline in cognition are needed urgently. Intensive research efforts in preclinical models have provided numerous hypotheses about the interaction between insulin resistance and neurodegeneration through a plethora of pathways. There is not enough evidence to provide specific recommendations to prevent the cognitive decline in individuals with or at high risk of type 2 diabetes [80].

Approximately 60% of elderly adults with diabetes have at least one comorbid chronic disease [81], and as many as 40% of them have four or more comorbid diseases [82]. Early diagnosis of cognitive impairment and the identification of the subset of patients at a higher risk of developing AD is a challenge for healthcare providers. Most of the diabetes care guidelines typically focus on decreasing diabetes-related microvascular and cardiovascular complications, as well the prevention of hypoglycemia, as strategies to account for cognitive dysfunction in the tailoring of glycemic therapy, and do not suggest specific diets, exercise routines, or pharmacological agents [83]. Several ongoing trials are attempting to identify the usefulness of several compounds, as well as lifestyle changes including exercise and diet.

Acknowledgments

The author thanks the South Texas Diabetes and Obesity Institute for support during the preparation of this review.

Funding/Support

1R01AG036469-05 from the National Institute on Aging and Fogarty International Center

Abbreviations

Aβ	Amyloid β -peptide
AChEI	Acetylcholinesterase inhibitors
AD	Alzheimer's Disease
AMPA	α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
APOE	Apolipoprotein E
BDPP	Bioactive Dietary Polyphenol Preparation

CSF	Cerebral Spinal Fluid
GABA	gamma-aminobutyric acid
GLP1	Glucagon-Like Peptide 1
HOMA2-IR	Homeostasis Model Assessment of Insulin Resistance
IL-6	Interleukine 6
MCI	Mild Cognitive Impairment
NMDA	<i>N</i> -methyl-D-aspartate
TNF	Tumor Necrosis Factor

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
 - Of major importance
1. Prince, M. World Alzheimer Report 2015: The global impact of dementia. London: Alzheimer's Disease International; 2015.
 2. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. *Lancet Neurol.* 2011; 10(9):819–28. DOI: 10.1016/S1474-4422(11)70072-2 [PubMed: 21775213]
 3. Portero McLellan KC, Wyne K, Villagomez ET, Hsueh WA. Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. *Ther Clin Risk Manag.* 2014; 10:173–88. DOI: 10.2147/TCRM.S39564 [PubMed: 24672242]
 - 4. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and Trends in Diabetes Among Adults in the United States, 1988–2012. *JAMA.* 2015; 314(10):1021–9. Presents a recent prevalence estimates of diabetes in the United States. DOI: 10.1001/jama.2015.10029 [PubMed: 26348752]
 5. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet.* 2012; 380(9859):2095–128. DOI: 10.1016/S0140-6736(12)61728-0 [PubMed: 23245604]
 6. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. *Lancet Neurol.* 2006; 5(1):64–74. DOI: 10.1016/S1474-4422(05)70284-2 [PubMed: 16361024]
 7. Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. *Intern Med J.* 2012; 42(5):484–91. DOI: 10.1111/j.1445-5994.2012.02758.x [PubMed: 22372522]
 8. Chowder I, Lavy S, Halpern L. Effect of insulin administered intracisternally in dogs on the glucose level of the blood and cerebrospinal fluid. *Experimental Neurology.* 1961; 3(2):197–205.
 9. Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. *Nature.* 1978; 272(5656):827–9. [PubMed: 205798]
 10. Hill JM, Lesniak MA, Pert CB, Roth J. Autoradiographic localization of insulin receptors in rat brain: prominence in olfactory and limbic areas. *Neuroscience.* 1986; 17(4):1127–38. [PubMed: 3520377]
 11. Francis H, Stevenson R. The longer-term impacts of Western diet on human cognition and the brain. *Appetite.* 2013; 63:119–28. DOI: 10.1016/j.appet.2012.12.018 [PubMed: 23291218]

12. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intranasal insulin therapy for Alzheimer disease and amnesic mild cognitive impairment: a pilot clinical trial. *Arch Neurol.* 2012; 69(1):29–38. DOI: 10.1001/archneurol.2011.233 [PubMed: 21911655]
13. Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, et al. Long Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzheimer’s Disease Dementia. *J Alzheimers Dis.* 2015; 45(4):1269–70. DOI: 10.3233/JAD-159002 [PubMed: 25869922]
14. Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH, et al. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer’s Disease Biomarkers: A Pilot Clinical Trial. *J Alzheimers Dis.* 2017; 57(4):1325–34. DOI: 10.3233/JAD-161256 [PubMed: 28372335]
15. Luchsinger JA, Perez T, Chang H, Mehta P, Steffener J, Pradabhan G, et al. Metformin in Amnesic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial. *J Alzheimers Dis.* 2016; 51(2):501–14. DOI: 10.3233/JAD-150493 [PubMed: 26890736]
16. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam Study. *Diabetologia.* 1996; 39(11):1392–7. [PubMed: 8933010]
17. Ruis C, Biessels GJ, Gorter KJ, van den Donk M, Kappelle LJ, Rutten GE. Cognition in the early stage of type 2 diabetes. *Diabetes Care.* 2009; 32(7):1261–5. DOI: 10.2337/dc08-2143 [PubMed: 19366968]
18. Crichton GE, Elias MF, Buckley JD, Murphy KJ, Bryan J, Frisardi V. Metabolic syndrome, cognitive performance, and dementia. *J Alzheimers Dis.* 2012; 30(Suppl 2):S77–87. DOI: 10.3233/JAD-2011-111022 [PubMed: 21971405]
19. Reijmer YD, van den Berg E, Ruis C, Kappelle LJ, Biessels GJ. Cognitive dysfunction in patients with type 2 diabetes. *Diabetes Metab Res Rev.* 2010; 26(7):507–19. DOI: 10.1002/dmrr.1112 [PubMed: 20799243]
- 20••. Koekkoek PS, Kappelle LJ, van den Berg E, Rutten GE, Biessels GJ. Cognitive function in patients with diabetes mellitus: guidance for daily care. *Lancet Neurol.* 2015; 14(3):329–40. Provides a review about general cognition that should be considered in the care of people with diabetes. DOI: 10.1016/S1474-4422(14)70249-2 [PubMed: 25728442]
21. Geijselaers SLC, Sep SJS, Schram MT, van Boxtel MPJ, Henry RMA, Verhey FRJ, et al. Insulin resistance and cognitive performance in type 2 diabetes - The Maastricht study. *J Diabetes Complications.* 2017; 31(5):824–30. DOI: 10.1016/j.jdiacomp.2017.01.020 [PubMed: 28319003]
22. Blazquez E, Velazquez E, Hurtado-Carneiro V, Ruiz-Albusac JM. Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer’s disease. *Front Endocrinol (Lausanne).* 2014; 5:161.doi: 10.3389/fendo.2014.00161 [PubMed: 25346723]
23. Fernandez AM, Torres-Aleman I. The many faces of insulin-like peptide signalling in the brain. *Nat Rev Neurosci.* 2012; 13(4):225–39. DOI: 10.1038/nrn3209 [PubMed: 22430016]
24. Potau N, Escofet MA, Martinez MC. Ontogenesis of insulin receptors in human cerebral cortex. *J Endocrinol Invest.* 1991; 14(1):53–8. DOI: 10.1007/BF03350263 [PubMed: 1646251]
25. Ghasemi R, Haeri A, Dargahi L, Mohamed Z, Ahmadiani A. Insulin in the brain: sources, localization and functions. *Mol Neurobiol.* 2013; 47(1):145–71. DOI: 10.1007/s12035-012-8339-9 [PubMed: 22956272]
26. Bilotta F, Lauretta MP, Tewari A, Haque M, Hara N, Uchino H, et al. Insulin and the Brain: A Sweet Relationship With Intensive Care. *J Intensive Care Med.* 2017; 32(1):48–58. DOI: 10.1177/0885066615594341 [PubMed: 26168800]
27. Pardridge WM, Kang YS, Buciak JL, Yang J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. *Pharm Res.* 1995; 12(6):807–16. [PubMed: 7667183]
28. Baura GD, Foster DM, Porte D Jr, Kahn SE, Bergman RN, Cobelli C, et al. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. *J Clin Invest.* 1993; 92(4):1824–30. DOI: 10.1172/JCI116773 [PubMed: 8408635]

29. Xaio H, Banks WA, Niehoff ML, Morley JE. Effect of LPS on the permeability of the blood-brain barrier to insulin. *Brain Res.* 2001; 896(1–2):36–42. [PubMed: 11277970]
30. Baura GD, Foster DM, Kaiyala K, Porte D Jr, Kahn SE, Schwartz MW. Insulin transport from plasma into the central nervous system is inhibited by dexamethasone in dogs. *Diabetes.* 1996; 45(1):86–90. [PubMed: 8522065]
31. Craft S, Cholerton B, Baker LD. Insulin and Alzheimer’s disease: untangling the web. *J Alzheimers Dis.* 2013; 33(Suppl 1):S263–75. DOI: 10.3233/JAD-2012-129042 [PubMed: 22936011]
32. Correia SC, Santos RX, Carvalho C, Cardoso S, Candeias E, Santos MS, et al. Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer’s disease and diabetes interrelation. *Brain Res.* 2012; 1441:64–78. DOI: 10.1016/j.brainres.2011.12.063 [PubMed: 22290178]
33. Ghasemi R, Dargahi L, Haeri A, Moosavi M, Mohamed Z, Ahmadiani A. Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders. *Mol Neurobiol.* 2013; 47(3):1045–65. DOI: 10.1007/s12035-013-8404-z [PubMed: 23335160]
34. Westwood S, Liu B, Baird AL, Anand S, Nevado-Holgado AJ, Newby D, et al. The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology. *Alzheimers Res Ther.* 2017; 9(1):31. doi: 10.1186/s13195-017-0258-6 [PubMed: 28441961]
35. Zemva J, Schubert M. The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer’s disease: possible therapeutic implications. *CNS Neurol Disord Drug Targets.* 2014; 13(2):322–37. [PubMed: 24059318]
36. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. *J Pharmacol Exp Ther.* 2002; 302(3): 881–8. DOI: 10.1124/jpet.102.037481 [PubMed: 12183643]
37. Bomfim TR, Fornyi-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease-associated Abeta oligomers. *J Clin Invest.* 2012; 122(4):1339–53. DOI: 10.1172/JCI57256 [PubMed: 22476196]
38. Talbot K, Wang HY. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer’s disease. *Alzheimers Dement.* 2014; 10(1 Suppl):S12–25. DOI: 10.1016/j.jalz.2013.12.007 [PubMed: 24529520]
39. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. *J Alzheimers Dis.* 2010; 19(4):1205–19. DOI: 10.3233/JAD-2010-1314 [PubMed: 20308787]
40. Xu W, Yang Y, Yuan G, Zhu W, Ma D, Hu S. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes. *J Investig Med.* 2015; 63(2):267–72. DOI: 10.1097/JIM.0000000000000129
41. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, et al. Exenatide and the treatment of patients with Parkinson’s disease. *J Clin Invest.* 2013; 123(6):2730–6. DOI: 10.1172/JCI68295 [PubMed: 23728174]
42. Pavlov VA, Parrish WR, Rosas-Ballina M, Ochani M, Puerta M, Ochani K, et al. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. *Brain Behav Immun.* 2009; 23(1):41–5. DOI: 10.1016/j.bbi.2008.06.011 [PubMed: 18639629]
43. Satapathy SK, Ochani M, Dancho M, Hudson LK, Rosas-Ballina M, Valdes-Ferrer SI, et al. Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice. *Mol Med.* 2011; 17(7–8):599–606. DOI: 10.2119/molmed.2011.00083 [PubMed: 21738953]
44. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s disease. *Lancet Neurol.* 2015; 14(4):388–405. DOI: 10.1016/S1474-4422(15)70016-5 [PubMed: 25792098]

45. Balion C, Griffith LE, Striffler L, Henderson M, Patterson C, Heckman G, et al. Vitamin D, cognition, and dementia: a systematic review and meta-analysis. *Neurology*. 2012; 79(13):1397–405. DOI: 10.1212/WNL.0b013e31826c197f [PubMed: 23008220]
46. Etgen T, Sander D, Bickel H, Sander K, Forstl H. Vitamin D deficiency, cognitive impairment and dementia: a systematic review and meta-analysis. *Dement Geriatr Cogn Disord*. 2012; 33(5):297–305. DOI: 10.1159/000339702 [PubMed: 22759681]
47. Shen L, Ji HF. Vitamin D deficiency is associated with increased risk of Alzheimer's disease and dementia: evidence from meta-analysis. *Nutr J*. 2015; 14:76. doi: 10.1186/s12937-015-0063-7 [PubMed: 26231781]
48. Landel V, Annweiler C, Millet P, Morello M, Feron F. Vitamin D, Cognition and Alzheimer's Disease: The Therapeutic Benefit is in the D-Tails. *J Alzheimers Dis*. 2016; 53(2):419–44. DOI: 10.3233/JAD-150943 [PubMed: 27176073]
49. Kennedy DO, Wightman EL, Reay JL, Lietz G, Okello EJ, Wilde A, et al. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. *Am J Clin Nutr*. 2010; 91(6):1590–7. DOI: 10.3945/ajcn.2009.28641 [PubMed: 20357044]
50. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. *Nutr Res*. 2012; 32(7):537–41. DOI: 10.1016/j.nutres.2012.06.003 [PubMed: 22901562]
51. Witte AV, Kerti L, Margulies DS, Floel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. *J Neurosci*. 2014; 34(23):7862–70. DOI: 10.1523/JNEUROSCI.0385-14.2014 [PubMed: 24899709]
52. Tome-Carneiro J, Larrosa M, Gonzalez-Sarrias A, Tomas-Barberan FA, Garcia-Conesa MT, Espin JC. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. *Curr Pharm Des*. 2013; 19(34):6064–93. [PubMed: 23448440]
53. Azorin-Ortuno M, Yanez-Gascon MJ, Vallejo F, Pallares FJ, Larrosa M, Lucas R, et al. Metabolites and tissue distribution of resveratrol in the pig. *Mol Nutr Food Res*. 2011; 55(8):1154–68. DOI: 10.1002/mnfr.201100140 [PubMed: 21710561]
54. Andersen G, Burkon A, Sulzmaier FJ, Walker JM, Leckband G, Fuhst R, et al. High dose of dietary resveratrol enhances insulin sensitivity in healthy rats but does not lead to metabolite concentrations effective for SIRT1 expression. *Mol Nutr Food Res*. 2011; 55(8):1197–206. DOI: 10.1002/mnfr.201100292 [PubMed: 21732533]
55. Marchal J, Pifferi F, Aujard F. Resveratrol in mammals: effects on aging biomarkers, age-related diseases, and life span. *Ann N Y Acad Sci*. 2013; 1290:67–73. DOI: 10.1111/nyas.12214 [PubMed: 23855467]
56. Akar F, Pektas MB, Tufan C, Soylemez S, Sepici A, Ulus AT, et al. Resveratrol shows vasoprotective effect reducing oxidative stress without affecting metabolic disturbances in insulin-dependent diabetes of rabbits. *Cardiovasc Drugs Ther*. 2011; 25(2):119–31. DOI: 10.1007/s10557-010-6255-7 [PubMed: 20676927]
57. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. *Diabetes*. 2013; 62(4):1186–95. DOI: 10.2337/db12-0975 [PubMed: 23193181]
58. Bo S, Ponzio V, Evangelista A, Ciccone G, Goitre I, Saba F, et al. Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial. *Acta Diabetol*. 2017; 54(5):499–507. DOI: 10.1007/s00592-017-0977-y [PubMed: 28238190]
59. Evans HM, Howe PR, Wong RH. Effects of Resveratrol on Cognitive Performance, Mood and Cerebrovascular Function in Post-Menopausal Women; A 14-Week Randomised Placebo-Controlled Intervention Trial. *Nutrients*. 2017; 9(1)doi: 10.3390/nu9010027
60. Wong RH, Nealon RS, Scholey A, Howe PR. Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus. *Nutr Metab Cardiovasc Dis*. 2016; 26(5):393–9. DOI: 10.1016/j.numecd.2016.03.003 [PubMed: 27105868]

61. Kobe T, Witte AV, Schnelle A, Tesky VA, Pantel J, Schuchardt JP, et al. Impact of Resveratrol on Glucose Control, Hippocampal Structure and Connectivity, and Memory Performance in Patients with Mild Cognitive Impairment. *Front Neurosci.* 2017; 11:105.doi: 10.3389/fnins.2017.00105 [PubMed: 28326010]
62. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. *Lancet Neurol.* 2014; 13(8):788–94. DOI: 10.1016/S1474-4422(14)70136-X [PubMed: 25030513]
63. Ngandu T, Lehtisalo J, Solomon A, Levalhti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. *Lancet.* 2015; 385(9984):2255–63. DOI: 10.1016/S0140-6736(15)60461-5 [PubMed: 25771249]
64. Richard F, Pasquier F. Can the treatment of vascular risk factors slow cognitive decline in Alzheimer's disease patients? *J Alzheimers Dis.* 2012; 32(3):765–72. DOI: 10.3233/JAD-2012-121012 [PubMed: 22886010]
65. Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. *Neurology.* 2011; 76(17):1485–91. DOI: 10.1212/WNL.0b013e318217e7a4 [PubMed: 21490316]
66. Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. *Neurology.* 2009; 73(9):674–80. DOI: 10.1212/WNL.0b013e3181b59bf3 [PubMed: 19720973]
67. Richard E, Kuiper R, Dijkgraaf MG, Van Gool WA. Evaluation of Vascular care in Alzheimer's d. Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial. *J Am Geriatr Soc.* 2009; 57(5):797–805. [PubMed: 19484836]
68. Rapp SR, Luchsinger JA, Baker LD, Blackburn GL, Hazuda HP, Demos-McDermott KE, et al. Effect of a Long-Term Intensive Lifestyle Intervention on Cognitive Function: Action for Health in Diabetes Study. *J Am Geriatr Soc.* 2017; doi: 10.1111/jgs.14692
69. Koch M, Jensen MK. Dietary patterns, Alzheimer's disease and cognitive decline: recent insights. *Curr Opin Lipidol.* 2017; 28(1):79–80. DOI: 10.1097/MOL.0000000000000376 [PubMed: 28030452]
70. Deckers K, van Boxtel MP, Schiepers OJ, de Vugt M, Munoz Sanchez JL, Anstey KJ, et al. Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies. *Int J Geriatr Psychiatry.* 2015; 30(3):234–46. DOI: 10.1002/gps.4245 [PubMed: 25504093]
- 71••. Pettersson SD, Philippou E. Mediterranean Diet, Cognitive Function, and Dementia: A Systematic Review of the Evidence. *Adv Nutr.* 2016; 7(5):889–904. Provides a review of evidence about the role of the mediterranean diet and cognition in old age. DOI: 10.3945/an.116.012138 [PubMed: 27633105]
72. Tomata Y, Sugiyama K, Kaiho Y, Honkura K, Watanabe T, Zhang S, et al. Dietary Patterns and Incident Dementia in Elderly Japanese: The Ohsaki Cohort 2006 Study. *J Gerontol A Biol Sci Med Sci.* 2016; 71(10):1322–8. DOI: 10.1093/gerona/glw117 [PubMed: 27356978]
73. Ozawa M, Shipley M, Kivimaki M, Singh-Manoux A, Brunner EJ. Dietary pattern, inflammation and cognitive decline: The Whitehall II prospective cohort study. *Clin Nutr.* 2017; 36(2):506–12. DOI: 10.1016/j.clnu.2016.01.013 [PubMed: 26874911]
74. Philippou E, Constantinou M. The influence of glycemic index on cognitive functioning: a systematic review of the evidence. *Adv Nutr.* 2014; 5(2):119–30. DOI: 10.3945/an.113.004960 [PubMed: 24618754]
- 75••. Yusuf M, Weyandt LL, Piryatinsky I. Alzheimer's disease and diet: a systematic review. *Int J Neurosci.* 2017; 127(2):161–75. A systematic review that summarizes the evidence considering diet as a protective or risk factor for Alzheimer's disease. DOI: 10.3109/00207454.2016.1155572 [PubMed: 26887612]
76. Fiocco AJ, Shatenstein B, Ferland G, Payette H, Belleville S, Kergoat MJ, et al. Sodium intake and physical activity impact cognitive maintenance in older adults: the NuAge Study. *Neurobiol Aging.* 2012; 33(4):829, e21–8. DOI: 10.1016/j.neurobiolaging.2011.07.004

77. Mattson MP, Allison DB, Fontana L, Harvie M, Longo VD, Malaisse WJ, et al. Meal frequency and timing in health and disease. *Proc Natl Acad Sci U S A*. 2014; 111(47):16647–53. DOI: 10.1073/pnas.1413965111 [PubMed: 25404320]
78. Solon-Biet SM, Mitchell SJ, de Cabo R, Raubenheimer D, Le Couteur DG, Simpson SJ. Macronutrients and caloric intake in health and longevity. *J Endocrinol*. 2015; 226(1):R17–28. DOI: 10.1530/JOE-15-0173 [PubMed: 26021555]
- 79••. Kullmann S, Heni M, Hallschmid M, Fritsche A, Preissl H, Haring HU. Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans. *Physiol Rev*. 2016; 96(4): 1169–209. Discusses recent findings about brain insulin resistance and its consequences. DOI: 10.1152/physrev.00032.2015 [PubMed: 27489306]
- 80••. Simo R, Ciudin A, Simo-Servat O, Hernandez C. Cognitive impairment and dementia: a new emerging complication of type 2 diabetes-The diabetologist's perspective. *Acta Diabetol*. 2017; 54(5):417–24. Discusses cognitive impact of diabetes in light of the care of the people with diabetes. DOI: 10.1007/s00592-017-0970-5 [PubMed: 28210868]
81. Lee PG, Cigolle C, Blaum C. The co-occurrence of chronic diseases and geriatric syndromes: the health and retirement study. *J Am Geriatr Soc*. 2009; 57(3):511–6. DOI: 10.1111/j.1532-5415.2008.02150.x [PubMed: 19187416]
82. Iglay K, Hannachi H, Joseph Howie P, Xu J, Li X, Engel SS, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. *Curr Med Res Opin*. 2016; 32(7): 1243–52. DOI: 10.1185/03007995.2016.1168291 [PubMed: 26986190]
- 83••. Marathe PH, Gao HX, Close KL. American Diabetes Association Standards of Medical Care in Diabetes 2017. *J Diabetes*. 2017; 9(4):320–4. Most recent guidelines for care of people with diabetes. DOI: 10.1111/1753-0407.12524 [PubMed: 28070960]

Table 1

Interventions for Cognitive Decline in Patients with or at Risk of Type 2

Study	Participants	Intervention	ClinicalTrials.gov Identifier	Country	Completion
Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease (COVARAD)	Diabetes Type 2, Hypertension or Dyslipidemia	Optimal care for vascular risk factors	NCT01423396	France	2020
Diet and Exercise Study to Improve Brain Blood Flow: Blood Flow Improvement Trial (BFIT)	Pre-diabetes	Diet and exercise	NCT03117829	United States	2018
BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (BDPP)	Diabetes Type 2 Pre-Diabetes	Resveratrol	NCT02502253	United States	2018
Effect of a Modified Ketogenic- Mediterranean Diet on Alzheimer's Disease (BEAM)	Pre-diabetes	Low- Carbohydrate vs Low-Fat Diet	NCT02984540	United States	2018
Can Vitamin D3 Improve Cognitive Function in Individuals With Type 2 Diabetes? (THINK-D)	Diabetes Type 2	Cholecalciferol	NCT02416193	United States	2018
Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function	Overweight or Obese	Intermittent dietary restriction	NCT02460783	United States	2017
Galantamine Effects in Patients With Metabolic Syndrome (GALANTA-MS)	Metabolic Syndrome	Galantamine	NCT02283242	Brazil	2017
Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients (DRINN)	Dysglycemia/Pre-diabetes	Exenatide	NCT02847403	Italy	2017
Macronutrient Effects on Alzheimer's Disease (MEAL-2 Diabetes)	Pre-diabetes	Low vs High glycaemic index Diet	NCT02463084	United States	2016